Author(s): Rutledge F, Smith JP, Franklin EW
Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma (VSCC) is an aggressive clinical entity. Current diagnostic guidelines for premalignant lesions are ambiguous, and their molecular profile and progression events are still unclear. We selected 75 samples, from 40 patients, including 33 VSCC, 8 verrucous carcinomas (VC), 13 differentiated-type vulvar intraepithelial neoplasia (dVIN), 11 suspicious for dVIN (?dVIN), 6 differentiated exophytic vulvar intraepithelial lesions (DE-VIL), 2 vulvar acanthosis with altered differentiation (VAAD), and 2 usual-type vulvar intraepithelial neoplasia (uVIN/HSIL). Invasive and precursor lesions were matched in 29 cases. Clinical information, p16 immunohistochemistry, and mutation analysis were performed on all lesions. All dVIN, ?dVIN, DE-VIL, and VAAD were p16 negative, all uVIN/HSIL were p16 positive. In the HPV-independent group, mutations were identified in 6 genes: TP53 (n = 40), PIK3CA (n = 20), HRAS (n = 12), MET (n = 5), PTEN (n = 4), and BRAF (n = 1). TP53 mutations occurred in 73% (22/30) VSCC, 85% (11/13) dVIN, 70% (7/10) ?dVIN and no VC (0/8), DE-VIL (0/6) nor VAAD (0/2). Basal atypia was the only reliable feature of TP53 mutations. ?dVIN lesions that were non-acanthotic and atypical but obscured by inflammation, all harbored TP53 mutations. In lesions without TP53 mutations, PIK3CA (50% VC, 33% DE-VIL, 100% VAAD, 40% VSCC) and HRAS (63% VC, 33% DE-VIL, 0% VAAD, 20% VSCC) mutations were found. Mutational progression from in situ to invasive was seen (7/26, 27%) and usually involved TP53 (4/26, 15%). Cases with TP53 and PIK3CA co-mutations had the worse clinical outcomes (p < 0.001). We recommend testing for p53 in all HPV-independent lesions suspicious for dVIN, even in the presence of marked inflammation or non-acanthotic skin, particularly when close to a margin. VC, VAAD, and DE-VIL, were almost never mutated for TP53, but instead often harbored PIK3CA and HRAS mutations. In VSCC, combined TP53 and PIK3CA mutations may inform prognosis.
Referred From: https://pubmed.ncbi.nlm.nih.gov/32792599/
Author(s): Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA
Author(s): Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG
Author(s): Jones RW, Baranyai J, Stables S
Author(s): Taussig FJ
Author(s): Falconer AD, Hirschowitz L, Weeks J, Murdoch J; South West Gynaecology Tumour Panel
Author(s): Rhodes CA, Cummins C, Shafi MI
Author(s): Levenback C, Morris M, Burke TW, Gershenson DM, Wolf JK, et al.
Author(s): Micheletti L, Preti M, Zola P, Zanotto Valentino MC, Bocci C, et al.
Author(s): [No authors listed]
Author(s): Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S
Author(s): Boutselis JG
Author(s): Japaze H, Garcia-Bunuel R, Woodruff JD
Author(s): Benedet JL, Turko M, Fairey RN, Boyes DA
Author(s): Cavanagh D, Shepherd JH
Author(s): Cavanagh D, Roberts WS, Bryson SC, Marsden DE, Ingram JM, et al.
Author(s): Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG
Author(s): Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS
Author(s): Rodolakis A, Diakomanolis E, Voulgaris Z, Akrivos T, Vlachos G, et al.
Author(s): Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, et al.
Author(s): Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HY
Author(s): Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, et al.
Author(s): Dhar KK, Woolas RP
Author(s): Saito T, Kato K
Author(s): Marsden DE, Hacker NF
Author(s): Hoffman JS, Kumar NB, Morley GW
Author(s): Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS
Author(s): Monaghan JM, Hammond IG
Author(s): Lingard D, Free K, Wright RG, Battistutta D et al.
Author(s): Atamdede F, Hoogerland D
Author(s): Van Der Velden J, Kooyman CD, Van Lindert AC, Heintz A
Author(s): Rhodes CA, Cummins C, Shafi MI
Author(s): Reuben DB, Mor V, Hiris J
Author(s): Barnes EA, Thomas G
Author(s): Barbera L, Thomas G, Elit L, Covens A, Fyles A, et al.